Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by OneAscent Financial Services LLC

OneAscent Financial Services LLC grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 37.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 3,191 shares of the medical equipment provider’s stock after purchasing an additional 868 shares during the quarter. OneAscent Financial Services LLC’s holdings in Zimmer Biomet were worth $492,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Zimmer Biomet by 7.2% in the 3rd quarter. BlackRock Inc. now owns 15,656,741 shares of the medical equipment provider’s stock valued at $2,131,509,000 after buying an additional 1,057,690 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Zimmer Biomet by 5.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,756,997 shares of the medical equipment provider’s stock worth $1,301,582,000 after purchasing an additional 490,415 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Zimmer Biomet by 9.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,060,638 shares of the medical equipment provider’s stock worth $126,598,000 after purchasing an additional 90,062 shares during the last quarter. Ceredex Value Advisors LLC grew its holdings in shares of Zimmer Biomet by 18.0% in the 3rd quarter. Ceredex Value Advisors LLC now owns 1,049,724 shares of the medical equipment provider’s stock worth $143,160,000 after purchasing an additional 159,901 shares during the last quarter. Finally, Wedge Capital Management L L P NC grew its holdings in shares of Zimmer Biomet by 23.4% in the 3rd quarter. Wedge Capital Management L L P NC now owns 838,092 shares of the medical equipment provider’s stock worth $114,098,000 after purchasing an additional 158,772 shares during the last quarter. 87.17% of the stock is owned by institutional investors.

Shares of NYSE:ZBH opened at $162.95 on Thursday. The company has a market capitalization of $33.78 billion, a price-to-earnings ratio of 1,018.50, a P/E/G ratio of 4.32 and a beta of 1.34. The firm’s 50 day simple moving average is $150.81 and its 200 day simple moving average is $140.57. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.18 and a quick ratio of 1.02. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $74.37 and a fifty-two week high of $165.15.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 11th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.74. The business had revenue of $1.92 billion for the quarter, compared to the consensus estimate of $1.71 billion. Zimmer Biomet had a net margin of 0.52% and a return on equity of 10.07%. Zimmer Biomet’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the company posted $1.77 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 4.8 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Monday, December 28th will be issued a dividend of $0.24 per share. The ex-dividend date is Thursday, December 24th. This represents a $0.96 annualized dividend and a yield of 0.59%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 12.20%.

A number of brokerages have commented on ZBH. Northland Securities began coverage on shares of Zimmer Biomet in a report on Tuesday, October 20th. They set a “market perform” rating and a $150.00 price objective on the stock. SVB Leerink increased their price objective on shares of Zimmer Biomet from $167.00 to $175.00 and gave the stock an “outperform” rating in a report on Monday, December 14th. Evercore ISI raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $175.00 price objective on the stock in a report on Monday, January 4th. Argus increased their price objective on shares of Zimmer Biomet from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Thursday, December 24th. Finally, Cowen increased their price objective on shares of Zimmer Biomet from $130.00 to $150.00 and gave the stock a “market perform” rating in a report on Tuesday, October 27th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $157.88.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: Why do companies issue stock splits?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.